Administration

eXIOME 2026

eXpert  International  Oncology  MEeting  —  3rd Edition

eXIOME 2026

Applicability of Western Oncology Guidelines and Innovations in LMICs

November 12–14, 2026 Marmara Taksim Hotel · Istanbul, Turkey
Explore

Why Attend eXIOME 2026?

Global Expert Faculty

Learn from world-renowned oncologists and researchers sharing current evidence and clinical experience from leading cancer centres across 4 continents.

Science & Clinical Practice

Bridging the gap between the latest oncology research and real-world clinical applicability in Low & Middle Income Countries.

International Networking

Connect with 300+ oncology professionals from over 30 countries. Build lasting collaborations and research partnerships.

Abstract & Case Presentations

Submit your research or clinical cases. Selected abstracts will be presented in dedicated oral and poster sessions.

eXIOME 2026

The eXIOME (eXpert International Oncology MEeting) is dedicated to the applicability of Western oncology guidelines in Low- and Middle-Income Countries (LMICs).

At the heart of this 3rd edition: the Neoadjuvant-to-Adjuvant treatment continuum — bridging evidence and accessibility for locally advanced cancers.

Three days of science, interactive case-based discussions, expert panels, and symposia, bringing together leading oncologists from the Mediterranean region and beyond.

3
Days
8
Sessions
12
Oral Comms
6+
Keynotes

Venue & Logistics

Venue
Marmara Taksim Hotel
Taksim Square, Gümüşsuyu Mh.
No:1, 34437 Beyoğlu, Istanbul, Türkiye
Dates
November 12–14, 2026

Day 1 — Thu. Nov. 12 (Afternoon)
Day 2 — Fri. Nov. 13 (Full day)
Day 3 — Sat. Nov. 14 (Morning)
Badges
Badge distribution:
Thursday November 12th after 12:00
On-site at the Marmara Taksim Hotel entrance.
Logistics
UNICON Congress & Incentive & Event
Ms Hande Boyacioglu
hande@uniconmice.com

Organising Committee & International Faculty

Organising Committee

Pr Y. Belkacemi
Co-Chair
France
Pr A. Bounedjar
Co-Chair
Algeria
Pr J. Gligorov
Co-Chair
France
Pr R. Samlali
Co-Chair
Morocco

Local Committee — Turkey

Pr B. Atalar
Local Committee
Turkey
Pr N. Bese
Local Committee
Turkey
Pr Özlem Er
Local Committee
Turkey
Pr E. Özyar
Local Committee
Turkey
Pr U. Selek
Local Committee
Turkey
Pr S. Turkan
Local Committee
Turkey

International Faculty

Algeria
D. Belabdi
Algeria
A. Bounedjar
Algeria
I. Lahfa
Algeria
B. Larbaoui
Algeria
M. Oukkal
Algeria
S. Sami
Algeria
Belgium
A. Awada
Belgium
France
Y. Belkacemi
France
K. Debbi
France
I. Duquesne
France
S. Frikha
France
J. Gligorov
France
Y. Mahi
France
F. Penault-Llorca
France
J-Y. Pierga
France
N-H. To
France
Morocco
F-Z. Bellefkih
Morocco
Y. Bensouda
Morocco
N. Berrada
Morocco
L.K. El Hassani
Morocco
M. Maskrout
Morocco
S. Bekkouche
Morocco
K. Oualla
Morocco
R. Samlali
Morocco
H. Talib
Morocco
Poland
AM. Czarnecka
Poland
P. Rutkowski
Poland
Serbia
B. Kukic
Serbia
M. Marijanovic
Serbia
L. Popovic
Serbia
D. Tesanovic
Serbia
Switzerland
M. Ozsahin
Switzerland
P. Tsoutsou
Switzerland
Tunisia
H. Boussen
Tunisia
S. Kanoun
Tunisia
O. Nouri
Tunisia
Turkey
B. Atalar
Turkey
N. Bese
Turkey
M. Celayir
Turkey
Özlem Er
Turkey
G. Ergene
Turkey
Y. Erlap
Turkey
E. Esin
Turkey
P. Hurmuz
Turkey
B. Köylü
Turkey
V. Kayku
Turkey
Y.C. Öyken
Turkey
E. Özyar
Turkey
U. Selek
Turkey
Ö. Sönmez
Turkey
S. Turkan
Turkey
UAE
F. Geara
UAE

Symposium Speakers

Nikos Paragios
TheraPanacea
Cem Önal
United Imaging
Y.C. Öyken
Siemens Healthineers
B. Atalar
ELEKTA
Y. Mahi
Guardant Health
B. Atalar
VisionRT

Scientific Program

Thursday, November 12, 2026 — Afternoon Session
Applicability of Western Oncology Guidelines in LMICs: The Neoadjuvant-to-Adjuvant Treatment Continuum for Locally Advanced Cancers — From Minimal Requirements to Optimal Care: Bridging Evidence and Accessibility
✨ Opening Ceremony
13:30–14:00Opening
Opening Ceremony and Welcome AddressB. Atalar (Turkey) · Y. Belkacemi (France) · A. Bounedjar (Algeria) · J. Gligorov (France) · Özlem Er (Turkey) · E. Özyar (Turkey) · R. Samlali (Morocco) · U. Selek (Turkey) · S. Turkan (Turkey)30 min
💬 Session 1 — Primary Local Treatment Followed by Adjuvant Therapy — Limited Evidence Settings
👥 Chairpersons: H. Talib (Morocco), A. Bounedjar (Algeria), E. Özyar (Turkey)
14:00–14:20Keynote 1
Locally Advanced Cancers in LMICs: Challenges with New Diagnostic Tools and Innovative Therapeutic OptionsJ. Gligorov (France)20 min
14:20–14:40Case 1
Stage II Colon Cancer: Role of Tumor Biology in Guiding Adjuvant Chemotherapy vs. SurveillanceCase Presenter: M. Marijanovic (Serbia)
Panelist: B. Kukic (Serbia)
20 min
15:00–15:20Case 2
Stage III Colon Cancer: Is There a Rationale for Adjuvant Therapy De-escalation Based on Tumor Biology?Case Presenter: M. Celayir (Turkey)
Panelist: Özlem Er (Turkey)
20 min
15:20–16:00Case 3
High-Risk Hepatocellular Carcinoma: Evidence for Anti-PD-L1/Anti-VEGF Therapy After Surgery or AblationCase Presenter: S. Bekkouche (Morocco)
Panelist: H. Errihani (Morocco)
20 min
16:00–16:30☕ Break
Coffee Break
💬 Session 2 — Neoadjuvant Systemic Therapy Followed by Adjuvant Therapy — Limited Evidence Settings
👥 Chairpersons: H. Boussen (Tunisia), D. Tesanovic (Serbia), Y. Belkacemi (France)
16:30–16:50Keynote 2
The Neoadjuvant-to-Adjuvant Continuum in Prostate Cancer: Current Status and Future DirectionsP. Hurmuz (Turkey)20 min
16:50–17:10Case 4
Locally Advanced Esogastric Cancer: Role of Immunotherapy After Perioperative ChemotherapyCase Presenter: B. Köylü (Turkey)
Panelist: U. Selek (Turkey)
20 min
17:10–17:30Case 5
Rectal Adenocarcinoma (dMMR/MSI-H), Stage II–III: Anti-PD-1 Therapy (Dostarlimab) in the Neoadjuvant SettingCase Presenter: D. Belabdi (Algeria)
Panelist: M. Oukkal (Algeria)
20 min
17:30–17:50Case 6
Locally Advanced Soft Tissue Sarcoma: Multimodal Treatment Strategies and Emerging ApproachesCase Presenter: O. Nouri (Tunisia)
Panelist: S. Kanoun (Tunisia)
20 min
🎓 Session 3 — Advances Technologies and Artificial Intelligence in Health Care — Present and Future Perspectives
👥 Chairpersons: I. Lahfa (Algeria), U. Selek (Turkey), J. Gligorov (France)
17:50–18:10Symposium
AI: The Radiologist's Perspective — Current Approaches in Adaptive Radiotherapy: Technological Advances and Clinical Expectations [Symposium Sponsored by United Imaging]Cem Önal (Turkey)20 min
18:10–18:30Symposium
Seeing the Invisible, Achieving the Impossible: Precision Radiotherapy Powered by AINikos Paragios (TheraPanacea, France)20 min
18:30–18:50Keynote 3
AI Knows Best? Who Really Decides in the New World of Oncology?S. Frikha (France)20 min
18:50Closing
Closing Remarks
20:00🍽 Social
Mediterranean Scientific Societies Dinner
Friday, November 13, 2026 — Full-Day Program
The Neoadjuvant-to-Adjuvant Continuum — High-Level Evidence in Locally Advanced Cancers
🎗 Session 4 — Locally Advanced Breast Cancer — Neoadjuvant-to-Adjuvant Treatment Continuum: High-Level Evidence
👥 Chairpersons: A. Awada (Belgium), A. Bounedjar (Algeria), R. Samlali (Morocco)
08:30–08:50Keynote 4
Biomarker-Guided Treatment Strategy Across the Neoadjuvant-to-Adjuvant Continuum According to Breast Cancer Molecular SubtypesF. Penault-Llorca (France)20 min
🎯 HER2-Positive Stage II–III Locally Advanced Breast Cancer
08:50–09:10Lecture
Pathological Complete Response After Optimal Neoadjuvant Therapy: Standard of Care in the Adjuvant SettingN. Berrada (Morocco)20 min
09:10–09:30Lecture
Invasive Residual Disease After Optimal Neoadjuvant Therapy: Standard of Care in the Adjuvant SettingÖzlem Er (Turkey)20 min
09:30–10:00Panel
Expert Panel & Audience Vote: Optimizing the Neoadjuvant-to-Adjuvant Strategy in HER2+ LABC — Minimal Requirements vs. Optimal Care in LMICsDiscussant: J. Gligorov (France), Y. Belkacemi (France) — Audience Interactive Vote30 min
10:00–10:30☕ Break
Coffee Break
👥 Chairpersons: Y. Bensouda (Morocco), H. Boussen (Tunisia), P. Tsoutsou (Switzerland)
🎯 Triple-Negative Stage II–III Locally Advanced Breast Cancer
10:30–10:50Lecture
Pathological Complete Response After Optimal Neoadjuvant Therapy: Standard of Care in the Adjuvant SettingJ-Y. Pierga (France)20 min
10:50–11:10Lecture
Invasive Residual Disease After Optimal Neoadjuvant Therapy: Standard of Care in the Adjuvant SettingY. Erlap (Turkey)20 min
11:10–11:40Panel
Expert Panel & Audience Vote: Optimizing the Neoadjuvant-to-Adjuvant Strategy in TNBC — Minimal Requirements vs. Optimal Care in LMICsDiscussant: J. Gligorov (France), Y. Belkacemi (France) — Audience Interactive Vote30 min
👥 Chairpersons: L. Popovic (Serbia), J-Y. Pierga (France), N. Bese (Turkey)
🎯 Hormone Receptor-Positive, HER2 negative Stage II–III Locally Advanced Breast Cancer
11:40–12:00Lecture
High-Risk HR+ Breast Cancer Without Neoadjuvant Therapy: Standard of Care in the Adjuvant SettingÖ. Sönmez (Turkey)20 min
12:00–12:20Lecture
High-Risk HR+ Breast Cancer After Neoadjuvant Therapy: Standard of Care in the Adjuvant SettingA. Awada (Belgium)20 min
12:20–12:50Panel
Expert Panel & Audience Vote: Optimizing Type and Duration of Adjuvant Endocrine Therapy in HR+ LABC — Challenges in LMICsDiscussant: J. Gligorov (France), Y. Belkacemi (France) — Audience Interactive Vote30 min
12:50–14:00🍽 Lunch
Lunch Break
🫁 Session 5 — Non-Small Cell Lung Cancer (NSCLC) — Neoadjuvant-to-Adjuvant Treatment Continuum: High-Level Evidence
👥 Chairpersons: M. Ozsahin (Switzerland), M. Maskrout (Morocco), M. Oukkal (Algeria)
14:00–14:30Symposium
Shaping the Future of Radiation Therapy Through Innovation [Symposium Sponsored by Siemens Healthineers]Y.C. Öyken (Turkey)
14:30–14:50Lecture
NSCLC Stage IB–IIIA: Combined Chemo-Immunotherapy in the Neoadjuvant and Adjuvant Settings — Standard of CareL.K. El Hassani (Morocco)20 min
14:50–15:10Lecture
NSCLC Stage IB–IIIA: Surgical Considerations Following Neoadjuvant Chemo-ImmunotherapyG. Ergene (Turkey)20 min
15:10–15:40Panel
Expert Panel & Audience Vote: Optimizing Immunotherapy Type and Duration in NSCLC — Challenges and Adaptations for LMICsDiscussant: B. Atalar (Turkey), F. Geara (UAE), A. Awada (Belgium) — Audience Interactive Vote30 min
15:40–16:00Symposium
New Horizons and Advantages with MR Linac Radiotherapy [Symposium Sponsored by ELEKTA]B. Atalar (Turkey)
16:00–16:30☕ Break
Coffee Break
🔬 Session 6 — Resectable Melanoma — Neoadjuvant-to-Adjuvant Treatment Continuum: High-Level Evidence
👥 Chairpersons: N-H. To (France), F. Geara (UAE), J. Gligorov (France)
16:30–16:50Keynote 5
Efficacy of Neoadjuvant-Adjuvant Targeted Therapy in Borderline Resectable Melanoma: What Are the Challenges in LMICs?AM. Czarnecka (Poland)20 min
16:50–17:10Lecture
Stage III Resectable Melanoma: Immunotherapy in the Neoadjuvant-to-Adjuvant Continuum — Standard of Care in the Immunotherapy EraP. Rutkowski (Poland)20 min
17:10–17:30Lecture
Stage III Resectable Melanoma: Criteria for Immunotherapy Personalization According to the Pathologic ResponseV. Kayku (Turkey)20 min
17:30–18:00Panel
Expert Panel & Audience Vote: Optimizing Immunotherapy Type and Duration in Resectable Melanoma — Challenges and Adaptations for LMICsDiscussant: Y. Belkacemi (France), N-H. To (France), J. Gligorov (France) — Audience Interactive Vote30 min
18:00–18:20Symposium
Liquid Biopsy: State of the Art and Perspectives in Solid Tumors [Symposium Sponsored by Guardanthealth]Y. Mahi (France)
18:20–18:30Closing
Closing Remarks
20:00🍽 Social
"Meet-the-Expert" Dinner
Saturday, November 14, 2026 — Morning Session
Bladder Cancer — High-Level Evidence & AROME Junior Proffered Oral Communications
💧 Session 7 — Muscle-Invasive Bladder Cancer — Neoadjuvant-to-Adjuvant Treatment Continuum: High-Level Evidence
👥 Chairpersons: B. Larbaoui (Algeria), M. Ozsahin (Switzerland), F-Z. Bellefkih (Morocco)
08:30–08:50Keynote 6
Robotic Surgery in Urothelial Cancers: Focus on Bladder Cancer and Challenges for Implementation of Robotic Surgery in LMICsI. Duquesne (France)20 min
08:50–09:10Lecture
High-Risk Bladder Cancer: Standard of Care in the Neoadjuvant-to-Adjuvant ContinuumE. Esin (Turkey)20 min
09:10–09:30Lecture
Post-Cystectomy Management: Patient Selection and Optimization of Adjuvant Therapy in the Immunotherapy EraK. Oualla (Morocco)20 min
09:30–10:00Panel
Expert Panel & Audience Vote: Optimizing the Neoadjuvant-to-Adjuvant Strategy in High-Risk Bladder Cancer — Challenges and Adaptations for LMICsDiscussant: L. Popovic (Serbia), K. Oualla (Morocco) — Audience Interactive Vote30 min
10:00–10:30Symposium
Innovations and New Technologies [Symposium Sponsored by VisionRT]B. Atalar (Turkey)
10:30–11:00☕ Break
Coffee Break
🎤 Session 8 — Plenary Session: AROME Junior Proffered Oral Communications (Session Sponsored by AROME)
👥 Chairpersons: S. Sami (Algeria), P. Tsoutsou (Switzerland), S. Turkan (Turkey), K. Debbi (France)
Breast Cancer
11:00–11:10C1
M.A. Melzi, A. Bounedjar — Biological Heterogeneity and Advanced-Stage Presentation of Breast Cancer in AlgeriaAlgeria10 min
11:10–11:20C2
L. Feredj, N. Bouaraba, H. Ammour, Yd. Ouchfoun, S. Toudjine, S. Haddad, L. Ait Ahmed, D. Merrad, C. Sedkaoui — Localized Triple-Negative BC: From Innovation to Local Care RealitiesMedical Oncology Department, Cancer Treatment Center / University of Tizi Ouzou, Algeria10 min
11:20–11:30C3
A. Djelil, M. Oukkal, D. Belabdi — Real-World Experience with Neoadjuvant Chemotherapy Combined with a Pembrolizumab Biosimilar in Early Triple-Negative Breast Cancer: Pathological Response OutcomesMedical Oncology Department, Beni Messous University Hospital, Algiers, Algeria10 min
11:30–11:40C4
A. Hadžibeganović, E. Sokolović, T. Cerić, B. Hasanbegović, E. Bičakčić-Filipović, A. Kovačević, E. Čampara, L. Šikalo, E. Mameledžija-Pinjo, M. Zatović, S. Bešlija — Axillary Management in Luminal Breast Cancer: LMIC ChallengesClinical Center University of Sarajevo, Sarajevo; PhD student, University of Tuzla, Bosnia and Herzegovina10 min
11:40–11:50C5
M. Kerkeb, S. Difi, N. Ghiroufella, D. Mesli, S. Madani, A. Ladjeroud, S. Sami, E. Kerboua — Dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer: pCR evaluationMedical Oncology Department, Pierre et Marie Curie Center, Algiers, Algeria10 min
11:50–12:00C6
A. Laaouad, N. Aklouche, N.E. Kaim, F. Seghier — From Guidelines to Clinical Practice: HER2-Positive Breast Cancer Management Across the Neoadjuvant-to-Adjuvant Continuum in a LMICMedical Oncology Department, Sidi Ghiles Hospital, Blida 1 University, Blida, Algeria10 min
12:00–12:10C7
T. Rabehi, R. Bosc, P. Beaussart, Y. Belkacemi, K. Debbi — Aesthetic outcomes after DIEP flap breast reconstruction and radiotherapy: impact of radio-surgical sequencingAP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, France10 min
Bladder Cancer
12:10–12:20C8
R. Fayala, A. Chamsi, B. Naija, S. Sghaier, D. Yazid, R. Zanzouri, H. Hadj Abdallah, N. Bouzid, S. Kanoun, S. Tbessi, S. Tebra — Bladder Cancer Radiotherapy: A 30-Year Experience from a Tunisian Cancer CenterUniversity of Sousse, Faculty of Medicine of Sousse, Radiation Oncology Department, Farhat Hached Hospital, Sousse, Tunisia10 min
Lung Cancer
12:20–12:30C9
T. Rossy, E. Mamou, D. Lassoued, B. Abbar, F. Ksantini, J.-P. Spano — Long-term survival in lung cancer patients with brain metastases treated with upfront local therapy and immunotherapy: the PHOENIX retrospective cohortDepartment of Medical Oncology, AP-HP – Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France10 min
12:30–12:40C10
S. Bekouaci, A. Bounedjar — Landscape of Lung Cancer in AlgeriaLaboratory of Cancer Research of Blida / Medical Oncology Department, Anti Cancer Center of Blida, Algeria10 min
12:40–12:50C11
S. Umihanic, B. Babic, T. Ramic, A. Omerovic, Dz. Sadic, E. Alibasic, F. Umihanic — Perioperative NSCLC Care in Bosnia and Herzegovina: Real-World DataUniversity Clinical Center Tuzla, Clinic of Oncology and Radiotherapy, Bosnia and Herzegovina10 min
12:50–13:00C12
M. Bugarčić, O. Ivanov — Atezolizumab as Second-Line Treatment in Patients with NSCLC Progressing After Sequential ChemoradiotherapyRadiation Oncology Department, Institute for Pulmonary Diseases of Vojvodina; Clinic for Radiation Oncology, Institute for Oncology of Vojvodina; University of Novi Sad, Medical Faculty, Serbia10 min
🖼️ Poster Presentations (Session Sponsored by AROME)

Breast Cancer

P1
N. Bouaraba, L. Feredj, H. Ammour, D. Merrad, Yd. Ouchfoun, C. Sedkaoui — HER2-Positive Breast Cancer: Response to Neoadjuvant Chemotherapy – A Retrospective StudyDepartment of Medical Oncology, CLCC Draa Ben Khedda, Tizi Ouzou, Algeria
P3
N. Aklouche, A. Laaouad, N. Kaim, F. Seghier — Evaluation of Pathological Response after Neoadjuvant Chemo-Immunotherapy in Triple-Negative Breast Cancer: Experience of the Medical Oncology Department, Sidi Ghiles Hospital, 2025Medical Oncology Department, University Hospital of Sidi Ghiles / Saad Dahleb University of Blida, Faculty of Medicine, Algeria
P5
S. Challal, S. Ouzit, S. Ait Seddik, M. Oukkal, A. Kouchkar — HER2-Positive Breast Cancer: Pathological Complete Response following neoadjuvant treatment and associated factorsDepartment of Medical Oncology, Beni Messous University Hospital, Algiers; Department of Epidemiology and Preventive Medicine, Beni Messous University Hospital, Algiers; Department of Anatomic and Cytopathology and Molecular Pathology, Bejaia University Hospital (CHU), Algeria
P9
N. Abed-Benmelha, M. Oukkal — The role of ovarian suppression in the treatment of premenopausal women with hormone receptor-positive early-stage breast cancerMedical Oncology Department, Beni Messous University Hospital, Algiers, Algeria
P10
S. Ait Ouamer, A. Boudoukha, N. Haoui — Definitive Chemoradiotherapy for Triple-Negative BC: A Surgery-Free CaseRadiation Therapy Center, Blida, Algeria
P12
A. Gheribi, M.A. Melzi, R. Benkali, H. Idir, A. Bounedjar — Efficacy and Longitudinal Tumor Response to First-Line Trastuzumab–Pertuzumab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Real-World StudyDepartment of Medical Oncology, EHS Ligue Contre le Cancer (LCC) Blida, Algeria; Faculty of Medicine, University Saad Dahleb Blida 1, Algeria
P13
S. Umihanic, A. Huseinbasic, B. Babic, Z. Mesanovic Suljkanovic, E. Trumic, F. Umihanic — Perioperative Treatment of HER2-Positive Early Breast Cancer: A 5-Year Real-World Experience from a Tertiary CenterUniversity Clinical Center Tuzla, Clinic for Oncology and Radiotherapy, Bosnia and Herzegovina
P15
M.A. Melzi, F. Haideche, W.D. Bouzidi, R. Dahmani, R. Miloudi, A. Djellaoui, A. Bounedjar — Progressive Clinical Tumor Shrinkage and Its Association With Breast Pathological Complete Response During Neoadjuvant Therapy for HER2-Positive Breast Cancer: Real-World Data From the NEOTRAPSCAL StudyLaboratory of Cancer Research of Blida / Medical Oncology Department, Anti Cancer Center of Blida, Algeria
P16
A. Ben Haj Salem, R. Zanzouri, N. Bouzid, A. Boubaker, A. Chamsi, H. Haj Abdallah, D. Yazid, A. Falfoul, S. Kanoun, S. Tbessi, S. Tebra — Dosimetric Constraint Compliance and Safety Profile of FAST-FORWARD Ultra-Hypofractionated Radiotherapy Following MastectomyDepartment of Radiation Oncology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Hospital, Sousse, Tunisia
P17
A. Boubaker, R. Zanzouri, N. Bouzid, A. Ben Haj Salem, A. Chamsi, H. Haj Abdallah, D. Yazid, S. Kanoun, S. Tbessi, S. Tebra — Cardiac and Pulmonary Dose Exposure in HER2-Positive Breast Cancer: Impact of Laterality and TechniqueRadiotherapy Oncology Department of Farhat Hached Hospital, Sousse, Tunisia
P18
A. Boubaker, R. Zanzouri, N. Bouzid, A. Ben Haj Salem, A. Chamsi, H. Haj Abdallah, S. Kanoun, S. Tbessi, S. Tebra — Factors Associated with Acute Toxicity Following Hypofractionated Breast RadiotherapyRadiotherapy Oncology Department of Farhat Hached Hospital, Sousse, Tunisia
P22
A. Gheribi, M.A. Melzi, H. Idir, R. Benkali, A. Bounedjar — Immune Microenvironment of Triple-Negative Breast Cancer in Algeria: Tumor-Infiltrating Lymphocytes, PD-L1 Expression, and Clinicopathological AssociationsLaboratory of Cancer Research of Blida / Medical Oncology Department, Anti-Cancer Center (CLCC) of Blida, Algeria
P23
A. Boubaker, N. Bouzid, A. Ben Haj Salem, R. Zanzouri, O. Bettaieb, A. Chamsi, S. Kanoun, S. Tebra — Axillary Nodal Boost in Locoregional Breast Radiotherapy: Dosimetric Impact and Acute ToleranceRadiotherapy Oncology Department, Farhat Hached University Hospital, Sousse, Tunisia
P24
H. Idir, D. Hasnaoui, R. Benkali, S. Bekouaci, A. Bounedjar — Pathological Response Following Neoadjuvant Treatment for HER2-Positive Breast Cancer: Experience at the Blida Cancer Center, Algeria (2025–2026)Department of Medical Oncology, Anti Cancer Center of Blida; Faculty of Medicine, University of Blida 1, Algeria

Melanoma

P28
R. Sai, E. Kerboua — Complete Metabolic Response to Pembrolizumab in a Stage IV Anorectal Melanoma: A Case ReportDepartment of Oncology, CPMC, Algiers, Algeria
P29
R. Sai, E. Kerboua — Immune-related systemic ophthalmic toxicity secondary to adjuvant pembrolizumab: a young patient with stage III cutaneous melanomaDepartment of Medical Oncology, CPMC, Algiers, Algeria
P30
F. Aouamri, M.A. Melzi, Z. Mansour, W. Ouahioune, R. Dahmani, H. Bouazza, A. Bounedjar — Malignant transformation of a pigmented epithelioid melanocytoma (PEM) into multi-metastatic melanomaDepartment of Medical Oncology, EHC Blida; Faculty of Medicine, University of Blida 1; Department of Pathology, University Hospital of Blida, Algeria
P32
H. Zidane, A.I. Bahi, N. Zahi, M.K. Hadjar, H. Ghelam — Melanoma management at Mostaganem University Hospital, AlgeriaMedical Oncology Department, University Hospital of Mostaganem, Algeria
P33
S. Ouzit, D. Belabdi, S. Mahiddine, A. Djoumad, M. Oukkal — Immunotherapy as a Treatment of Melanoma: Real-Life ExperienceMedical Oncology Department, Beni Messous University Hospital, Algiers, Algeria

Bladder Cancer

P34
A. Ben Haj Salem, R. Zanzouri, N. Bouzid, A. Boubaker, A. Chamsi, H. Haj Abdallah, D. Yazid, A. Falfoul, S. Kanoun, S. Tbessi, S. Tebra — Bladder Cancer Radiotherapy: Compliance With Dose Constraints and Acute Treatment-Related ToxicitiesDepartment of Radiation Oncology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Hospital, Sousse, Tunisia
P36
Y. Rouizi, K. Bouallala, D. Metelaoui, M. Oukkal, S. Ouzit — Challenges in Treatment Sequencing for Bladder Cancer: A Case ReportDepartment of Medical Oncology, Beni Messous University Hospital Center, Algeria

Pancreatic Cancer

P37
S. Bekouaci, R. Benkali, H. Idir, A. Bounedjar — Is CA 19.9 a Prognostic Predictor in Advanced or Metastatic Pancreatic CancerDepartment of Medical Oncology, Anti-Cancer Center (CLCC) of Blida, Algeria

Abstract Submission Guidelines

📅 Deadline: Monday, October 26th, 2026

Submit to: yazid.belkacemi@aphp.fr  —  CC: fadila.chekiri@aphp.fr

📋 Formal Requirements

Format

  • Maximum 350 words
  • Font: Times New Roman 12pt, spacing 1.5
  • File: Word (.doc / .docx)
  • Maximum one page (incl. figures & references)
  • Margins: Top & Bottom 2.5 cm, Left & Right 1.5 cm

Typography

  • Title: 14pt, Bold, centered
  • Authors: 12pt, centered (underline presenting author)
  • Affiliations & email: 11pt, centered
  • Main text: 12pt, justified
  • References: 11pt, square brackets [1]

📐 Abstract Structure

  • 1. Title (max 70 chars)
  • 2. Introduction
  • 3. Objectives
  • 4. Material & Methods
  • 5. Results
  • 6. Conclusion

🎯 Accepted Topics — Please indicate in your abstract title

🎗 Breast Cancers
  • Luminal A BC
  • Luminal B BC
  • Triple Negative BC
  • HER2 Positive BC
  • Neoadjuvant locoregional therapy
  • Others translational study
🫁 Lung Cancers
  • Neoadjuvant therapeutic strategy
  • Locoregional therapy
  • Immunotherapy and new drugs
  • Others translational study
🔬 Melanoma
  • Immunotherapy and new drugs
  • Locoregional therapy
  • Others translational study
💧 Bladder Cancers
  • Neoadjuvant therapy
  • Surgery / Radiotherapy
  • Immunotherapy and new drugs
  • Others translational study

🎤 Type of Presentation — Please specify in your email

🎤 Oral presentation only
🖼️ Poster presentation only
🎤/🖼️ Oral or Poster

📥 Speaker Slide Template

For a harmonised look
Speakers and presenters: use the official eXIOME 2026 slide template — same colours, typography and layout as this website.
Download Template (.pptx) →

Our Partner Societies

Sponsors

These laboratories are not official sponsors of eXIOME 2026 — they generously support the attendance of local guests (AlgenPharm, Axess Pharma, OrionLab, Hikma, Ipsen, Oncorad Group).

Admin Panel

Edit the site content below.

🔑 Change Admin Password

📢 Announcement Banner

👤 Add Speaker

🎨 Site Colours

Edit the site's main colours in real time.

🖼️ Photo Management

Import and insert photos into any section of the site.

📅 Program Editor

Add, edit or remove sessions in the program.

Site Colours

Edit in real time
Main Background (Navy)
Secondary Background (Deep)
Gold Accent
Light Accent
Main Text
Muted Text

Preset Themes:

Photo Manager

Import and insert photos
📸

Click or drag and drop your photos here

JPG, PNG, WebP accepted


Insert a photo into:

Program Editor

Manage sessions by day

You can also double-click a program row to edit it directly.

eXIOME 2026 — November 12–14 · Istanbul  |  Registrations are open

Register Now →